AGTC to Present at Upcoming Gene Therapy Conferences
September 29 2017 - 7:00AM
Applied Genetic Technologies Corporation (NASDAQ:AGTC), a
biotechnology company conducting human clinical trials of
adeno-associated virus (AAV)-based gene therapies for the treatment
of rare and debilitating diseases, today announced that management
will be participating in the following conferences:
- Alliance for Regenerative Medicine
(ARM)'s Cell & Gene
Meeting on the Mesa – La Jolla, Calif. (October 4-6,
2017)AGTC President & CEO Sue Washer will deliver a
company presentation at 11:15am PT on October 4. Ms. Washer will
also moderate a panel discussion titled “Gene Therapy: Building the
Gene Medicine Pipeline Through Next Generation Technologies” at
4:00pm PT the same day.
- Chardan Gene Therapy Conference – New York (October 10,
2017)Ms. Washer will participate in an analyst-led
fireside chat at 3:15pm ET. A live audio webcast of the
presentation will be accessible by
visiting ir.agtc.com/events.cfm. A replay will be available on
the company's website following the event. Ms. Washer will also
participate in a panel discussion titled “Gene Therapies: Pricing
and Other Commercial Considerations” at 4:15pm ET.
About AGTC
AGTC is a clinical-stage biotechnology company that uses a
proprietary gene therapy platform to develop transformational
genetic therapies for patients suffering from rare and debilitating
diseases. Its initial focus is in the field of ophthalmology,
where it has active clinical trials in X-linked retinoschisis
(XLRS), X-linked retinitis pigmentosa (XLRP), and achromatopsia
(ACHM CNGB3 & ACHM CNGA3). In addition to its clinical
trials, AGTC has preclinical programs in optogenetics,
adrenoleukodystrophy (ALD), which is a disease of the central
nervous system (CNS), and otology. The clinical-stage XLRS and XLRP
programs, the discovery program in ALD and two additional
ophthalmology programs are being developed in collaboration with
Biogen. In addition to its product pipeline, AGTC has a significant
intellectual property portfolio and extensive expertise in the
design of gene therapy products including capsids, promoters and
expression cassettes, as well as expertise in the formulation,
manufacture and physical delivery of gene therapy
products.
IR/PR CONTACTS:
David Carey (IR) or Tom Vickery (PR)Lazar Partners Ltd.T: (212)
867-1768 or (646) 871-8482dcarey@lazarpartners.com or
tvickery@lazarpartners.com
CORPORATE CONTACTS:
Bill SullivanChief Financial OfficerApplied Genetic Technologies
CorporationT: (617) 843-5728 bsullivan@agtc.com
Stephen PotterChief Business OfficerApplied Genetic Technologies
CorporationT: (617) 413-2754spotter@agtc.com
Applied Genetic Technolo... (NASDAQ:AGTC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Applied Genetic Technolo... (NASDAQ:AGTC)
Historical Stock Chart
From Apr 2023 to Apr 2024